Firms, funds, partners, companies and rounds from sworn filings, firm sites and announcements, kept as a graph with a date and a source on every edge. Facts, inferences and estimates are labelled as such. A fund target is never a close, GAV is never dry powder, and a round size is never an investor’s check.

Companies / Aspen Neuroscience

Aspen Neuroscience

Series CUS
Facts
Year of incorporation
unknown
Revenue range (Form D)
unknown
Rounds on record
1
Disclosed raised
$115Msum of rounds with a disclosed amount only
Named investors
8
Financing history
1 rounds
  1. Nov 20, 2025
    Series C · $115M (disclosed)
    Arch Venture Partners (lead)Section 32, LLC (participant)Axon Ventures (participant)Balyasny Asset Management L.P. (participant)Cormorant Asset Management (participant)Prebys Ventures (participant)Orbimed Advisors LLC (lead)Lyfe Capital Management Limited (participant)
    Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS) · “Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs”
Investors on record
8 edges
People
0 officers, 0 directors
No officer or director on record.
Timeline
1
  1. Nov 20, 2025
    Aspen Neuroscience announced Series C of $115,000,000, led by OrbiMed, ARCH Venture Partners
    Round announced Fact Press release wires (Business Wire, PR Newswire, GlobeNewswire public RSS)
Evidence
1 observations
Every observation on this company